Safety of long-term use of daily and long-acting growth hormone in growth hormone-deficient adults on cancer risk

IF 6.1 1区医学 Q1 ENDOCRINOLOGY & METABOLISM

Best practice & research. Clinical endocrinology & metabolism Pub Date : 2023-12-01 DOI:10.1016/j.beem.2023.101817

Cesar Luiz Boguszewski (Full Professor of Endocrinology)

{"title":"Safety of long-term use of daily and long-acting growth hormone in growth hormone-deficient adults on cancer risk","authors":"Cesar Luiz Boguszewski (Full Professor of Endocrinology)","doi":"10.1016/j.beem.2023.101817","DOIUrl":null,"url":null,"abstract":"<div><p><span>Daily injections of recombinant human growth hormone (rhGH) have been used in clinical practice for almost four decades as a replacement therapy in adult patients with </span>GH deficiency<span> (GHD). Long-term adherence to daily injections of rhGH is a clinical concern that may result in reduced therapeutic efficacy, and long-acting GH (LAGH) formulations have been developed in an attempt of overcoming this problem. Long-term safety issues of rhGH are the other side of the coin that has been carefully monitored over the years, particularly related to the proliferative actions of GH that could increase the risk of tumor recurrence or induce the development of new benign and malignant tumors. In this review, we present what is currently known about the cancer risk in GHD adults treated with daily rhGH injections and we discuss the major concerns and responses needed from future surveillance studies regarding the safety of LAGH preparations.</span></p></div>","PeriodicalId":8810,"journal":{"name":"Best practice & research. Clinical endocrinology & metabolism","volume":"37 6","pages":"Article 101817"},"PeriodicalIF":6.1000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Best practice & research. Clinical endocrinology & metabolism","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1521690X2300091X","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Daily injections of recombinant human growth hormone (rhGH) have been used in clinical practice for almost four decades as a replacement therapy in adult patients with GH deficiency (GHD). Long-term adherence to daily injections of rhGH is a clinical concern that may result in reduced therapeutic efficacy, and long-acting GH (LAGH) formulations have been developed in an attempt of overcoming this problem. Long-term safety issues of rhGH are the other side of the coin that has been carefully monitored over the years, particularly related to the proliferative actions of GH that could increase the risk of tumor recurrence or induce the development of new benign and malignant tumors. In this review, we present what is currently known about the cancer risk in GHD adults treated with daily rhGH injections and we discuss the major concerns and responses needed from future surveillance studies regarding the safety of LAGH preparations.

查看原文本刊更多论文

生长激素缺乏成人长期使用每日和长效生长激素对癌症风险的安全性

每日注射重组人生长激素(rhGH)作为成人生长激素缺乏症(GHD)患者的替代疗法已经在临床实践中使用了近40年。长期坚持每日注射rhGH是一个临床问题，可能导致治疗效果降低，长效GH (LAGH)配方已经开发出来，试图克服这个问题。生长激素的长期安全性问题是硬币的另一面，多年来一直受到仔细监测，特别是与生长激素的增殖作用有关，生长激素可能增加肿瘤复发的风险或诱导新的良性和恶性肿瘤的发展。在这篇综述中，我们介绍了目前已知的每日注射rhGH治疗的GHD成人的癌症风险，并讨论了关于LAGH制剂安全性的未来监测研究中需要关注的主要问题和应对措施。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Best practice & research. Clinical endocrinology & metabolism 医学-内分泌学与代谢

CiteScore

11.90

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Best Practice & Research Clinical Endocrinology & Metabolism is a serial publication that integrates the latest original research findings into evidence-based review articles. These articles aim to address key clinical issues related to diagnosis, treatment, and patient management. Each issue adopts a problem-oriented approach, focusing on key questions and clearly outlining what is known while identifying areas for future research. Practical management strategies are described to facilitate application to individual patients. The series targets physicians in practice or training.